DATAROMA
Home
Commentaries/Articles
Superinvestors
Activity
S&P500 Grid
Grand Portfolio
RealTime
Insider
01 May 2016
Valeant’s CEO Was Key Force on Pricing
The day it completed its February 2015 purchase of the drug, called Nitropress, Valeant tripled the cost.
Home
Help notes
Contact
Terms of Service
Privacy